Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | JUN | P05412 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25538030 | 1.00 | KMT2A (0.41) | KMT2AMEN1LMNAKDM6BKDM4A | |
| SCHEMBL30873391 | 0.85 | KMT2A (0.43) | KMT2AMEN1LMNAKDM6BKDM4A | |
| SCHEMBL30923133 | 0.81 | PARP1 (0.53) | LMNAJUNNFKB1NFKB2RELA | |
| SCHEMBL26708633 | 0.76 | KRAS (0.45) | — | |
| SCHEMBL24984102 | 0.75 | HPGD (0.40) | KMT2ALMNAHTTXDHGFER | |
| SCHEMBL31103562 | 0.75 | HPGD (0.40) | KMT2ALMNAHTTXDHGFER | |
| SCHEMBL30873485 | 0.74 | HPGD (0.39) | KMT2ALMNAHTTXDHGFER | |
| SCHEMBL26892305 | 0.74 | HPGD (0.39) | KMT2ALMNAHTTXDHGFER | |
| SCHEMBL27309745 | 0.72 | LMNA (0.41) | KMT2AMEN1LMNAHTTXDH | |
| SCHEMBL21196101 | 0.72 | KMT2A (0.44) | KMT2ALMNAXBP1HTTPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2025072686-A1 | KRAS G12D MUTATION TARGETING COMPOUNDS | SUMMIT THERAPEUTICS INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025024732-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF KRAS MEDIATED DISORDERS | ARVINAS OPERATIONS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-118556063-A | Heterocyclic compound, pharmaceutical composition and application thereof | 上海湃隆生物科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024083168-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-117800975-A | Compounds with anti-KRAS mutant tumor activity | 泰励生物科技（上海）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023039240-A9 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023039240-A1 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | KMT2A 1675/4885MEN1 2222/4885LMNA 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.